CTMC is a joint venture between Resilience and the MD Anderson Cancer Center. It works like an internal manufacturing group, adapting to change in real time without charge ups and allowing for better control as a company develops their research process. With all of the resources in one circular supply chain (patients, clinicians, manufacturing, and regulatory), CTMC is executing the manufacturing and analytical processes while also supporting active engagement with MD Anderson, preparing to launch trials as soon as the FDA approves an IND.
CTMC provides biotech partners with access to MD Anderson’s clinical trial network, allowing therapies to be tested in patients without the biotech having to coordinate the trials themselves.
The recent Link announcement of $60m Series A financing led by Johnson & Johnson highlights the success of the partnership between CTMC and Link for advancing the development of CAR T therapies for solid tumours into the clinical stage.
Listen to the podcast here: https://rss.com/podcasts/base-to-base-biotech/2742798/